Restart Life Sciences Corp. is a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Their mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.
The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.